Table 2.

Mifepristone (50 mg·kg⁻¹) attenuates the somatic expression of naloxone-precipitated morphine withdrawal

	Two-way anova
	Chronic treatment (morphine vs. placebo)		Pretreatment (mifepristone vs. vehicle)		Interaction
Signs	F(1, 22)	P	F(1, 22)	P	F(1, 22)	P
Wet-dog shakes	26.26	≤0.0001	56.83	≤0.0001	22.07	≤0.0001
Tremor	4.72	≤0.05	26.17	≤0.0001	4.72	≤0.05
Sniffing	13.83	≤0.01	13.83	≤0.01	13.83	≤0.01
Teeth chattering	4.34	≤0.05	41.28	≤0.0001	4.34	≤0.05
Ptosis	15.79	≤0.0006	227.96	≤0.0001	15.79	≤0.0006
Piloerection	197.74	≤0.0001	236.65	≤0.0001	197.74	≤0.0001
Rinorrhoea	2.00	n.s.	16.76	≤0.0005	2.00	n.s.
Chromodacryorrhoea	7.60	≤0.05	27.53	≤0.0001	7.60	≤0.05
Weight loss	26.47	≤0.0001	19.64	≤0.0002	8.83	≤0.0070
Global score	26.06	≤0.0001	96.82	≤0.0001	26.06	≤0.0001

Two-way anova with chronic treatment (morphine vs. placebo) and pretreatment before naloxone (mifepristone 50 mg·kg⁻¹ vs. vehicle) as between-subject factors. When significant interactions in pretreatment or between these two factors were observed, subsequent post hoc test was applied.